Page 1 | Search Results | Blood | American Society of Hematology

1-13 of 13

Sort by

Sort Order Select

Journal Articles

Open-Label Pilot Study of Genetically Engineered NY-ESO-1 Specific T Cells (GSK3377794) Alone or in Combination with Pembrolizumab in Relapsed and Refractory Multiple Myeloma

Taiga Nishihori, MD, Jonathan L. Kaufman, MD, James E. Hoffman, Kristin Blouch, Sunil Pandit, Emily Butler, Amit Jain, Yuehui Wu, M. Phillip DeYoung, Aisha N. Hasan, Aaron P. Rapoport

Blood (2019) 134 (Supplement_1): 3134.

https://doi.org/10.1182/blood-2019-128059

Published: 2019

Journal Articles

Dual-Sensitized T-Cells Responding to EBV Blcl and Either CMVpp65 or WT-1 Peptide Pools Have Distinct or Shared HLA Restrictions That May Depend on the Presenting HLA Alleles

Ekaterina Doubrovina, MD PhD, Aisha N. Hasan, MD, Susan Prockop, MD, Karim Baroudy, MS, Richard O'Reilly, MD

Blood (2018) 132 (Supplement 1): 4596.

https://doi.org/10.1182/blood-2018-99-119001

Published: 2018

Journal Articles

Adoptive T-Cell Therapy with 3 rd Party CMV-pp65-Specific CTLs for CMV Viremia and Disease Arising after Allogeneic Hematopoietic Stem Cell Transplant

Susan Prockop, MD, Ekaterina Doubrovina, MD PhD, Irene Rodriguez-Sanchez, Aisha N. Hasan, MD, Juliet Barker, MBBS, H.R. Castro-Malaspina, MD, Parastoo B. Dahi, MD, Sergio A. Giralt, MD, Boglarka Gyurkocza, MD, Nancy A. Kernan, MD, Guenther Koehne, MDPhD, Esperanza B. Papadopoulos, MD, Doris Ponce, MD, Craig S. Sauter, MD, Virginia Escobedo, RN, Victoria Szenes, PNP, Karim Baroudy, BS, Alison Slocum, MA, Richard J. O'Reilly, MD

Blood (2017) 130 (Supplement 1): 747.

https://doi.org/10.1182/blood.V130.Suppl_1.747.747

Published: 2017

Journal Articles

Third Party CMV-Specific Cytotoxic T Cells for Treatment of Antiviral Resistant CMV Infection after Hematopoietic Stem Cell Transplant

Susan Prockop, MD, Ekaterina Doubrovina, MD PhD, Aisha N Hasan, MD, Parastoo B Dahi, MD, Sergio Giralt, MD, Guenther Koehne, MD PhD, Nancy A. Kernan, MD, Esperanza B Papadopoulos, MD, Rachel Lehrman, Irene Rodriguez-Sanchez, Richard J. O'Reilly, MD

Blood (2016) 128 (22): 61.

https://doi.org/10.1182/blood.V128.22.61.61

Published: 2016

Journal Articles

Adoptively Transferred CMV-Specific T-Cells Responsive to Immunodominant CMVpp65 Epitopes Extend Durable in-Vivo Suppression of Clonogenic CMVpp65 [+] Human Colon Carcinoma Cells in Comparison to T-Cells Responsive to Subdominant Epitopes

Aisha N Hasan, MD, Annamalai Selvakumar, PhD, Tzu-Yun Kuo, Richard J O'Reilly, MD

Blood (2015) 126 (23): 4298.

https://doi.org/10.1182/blood.V126.23.4298.4298

Published: 2015

Journal Articles

T- Cell Depleted Peripheral Blood Stem Cell (TCD-PBSC) Transplants Secure Consistent Engraftment with Low Risk of Acute or Chronic Gvhd and Favorable Disease Free Survival (DFS) and Overall Survival (OS) for Pediatric Patients (<21 years) with AML in CR1 or CR2 or MDS Including tMDS/AML

Nancy A. Kernan, MD, Farid Boulad, MD, Susan Prockop, MD, Suzanne Wolden, MD, Andromachi Scaradavou, MD, Rachel Kobos, Rachel Lehrman, Elizabeth Klein, MPH, Kevin J. Curran, MD, Aisha N Hasan, MD, Sharon Bleau, Julianne Ruggiero, PNP, Nicole Zakak, PNP, Anne Casson, PNP, Joanne Torok-Castanza, PNP, Richard J O'Reilly, MD

Blood (2015) 126 (23): 5513.

https://doi.org/10.1182/blood.V126.23.5513.5513

Published: 2015

Journal Articles

Banked, GMP Grade Third Party T-Cell Lines Specific for CMVpp65 Epitopes Presented By Certain Prevalent HLA Alleles More Consistently Clear CMV Infections in a Genetically Heterogeneous Population of HSCT Recipients

Aisha N. Hasan, MD, Susan E. Prockop, MD, Guenther Koehne, MD PhD, Ekaterina Doubrovina, MD PhD, Richard J. O'Reilly, MD

Blood (2014) 124 (21): 309.

https://doi.org/10.1182/blood.V124.21.309.309

Published: 2014

Journal Articles

Generation and Characterization Of a Third Party GMP Grade Bank Of CMV Specific T-Cells For Adoptive Immunotherapy Of CMV Infections In Recipients Of HSCT From Cord Blood Or Seronegative Donors

Aisha N. Hasan, MD, Ekaterina Doubrovina, MD, PhD, Guenther Koehne, MD, PhD, Susan E. Prockop, MD, Richard J. O'Reilly, MD

Blood (2013) 122 (21): 2021.

https://doi.org/10.1182/blood.V122.21.2021.2021

Published: 2013

Journal Articles

Two Chemotherapy-Based Conditioning Regimens Compared To TBI-Based Conditioning Secure Consistent Engraftment Of T-Cell Depleted Allogeneic HSCT, Similarly Low Incidences Of Gvhd and Favorable Rates Of Disease-Free Survival (DFS)

Blood (2013) 122 (21): 546.

https://doi.org/10.1182/blood.V122.21.546.546

Published: 2013

Journal Articles

Adoptive Immunotherapy with Donor T Cells Sensitized with Overlapping Pentadecapeptides of the CMV-pp65 Protein for the Treatment of Persistent CMV Antigenemia Following Allogeneic Hematopoietic Stem Cell Transplants

Blood (2012) 120 (21): 351.

https://doi.org/10.1182/blood.V120.21.351.351

Published: 2012

Journal Articles

Engineered Antigen- Presenting Cells Expressing Human HLA Class-II DR Alleles Support Efficient Enrichment and Expansion of Antigen Specific T h 1 CD4[+] T-Cells Which Are Functionally Augmented by IL-15Rα/IL-15 Complexes

Aisha N. Hasan, MD, Rosanna J. Ricafort, MD, Annamalai Selvakumar, PhD, Ekaterina Doubrovina, MD, PhD, Isabelle Riviere, Michel Sadelain, MD, PhD, Richard J. O'Reilly, MD

Blood (2012) 120 (21): 1905.

https://doi.org/10.1182/blood.V120.21.1905.1905

Published: 2012

Journal Articles

A Panel of Artificial Antigen Presenting Cells (AAPC) Permits Immediate Sensitization and Rapid Generation of Virus-Specific T-Cells of Desired HLA Restriction for Adoptive Immunotherapy.

Aisha N. Hasan, MD, Wouter J. Kollen, MD, PhD, Deepa Trivedi, MD, A. Selvakumar, PhD, Michel Sadelain, MD,PhD, Richard J. O’Reilly, MD

Blood (2006) 108 (11): 3268.

https://doi.org/10.1182/blood.V108.11.3268.3268

Published: 2006

Journal Articles

Re-Treatment with Rituximab in ITP: Comparison of Standard Dose with 2 Forms of Augmented Rituximab.

Aisha N. Hasan, MD, James B. Bussel, MD

Blood (2005) 106 (11): 1237.

https://doi.org/10.1182/blood.V106.11.1237.1237

Published: 2005

NARROW

Open-Label Pilot Study of Genetically Engineered NY-ESO-1 Specific T Cells (GSK3377794) Alone or in Combination with Pembrolizumab in Relapsed and Refractory Multiple Myeloma

Dual-Sensitized T-Cells Responding to EBV Blcl and Either CMVpp65 or WT-1 Peptide Pools Have Distinct or Shared HLA Restrictions That May Depend on the Presenting HLA Alleles

Adoptive T-Cell Therapy with 3 rd Party CMV-pp65-Specific CTLs for CMV Viremia and Disease Arising after Allogeneic Hematopoietic Stem Cell Transplant

Third Party CMV-Specific Cytotoxic T Cells for Treatment of Antiviral Resistant CMV Infection after Hematopoietic Stem Cell Transplant

Adoptively Transferred CMV-Specific T-Cells Responsive to Immunodominant CMVpp65 Epitopes Extend Durable in-Vivo Suppression of Clonogenic CMVpp65 [+] Human Colon Carcinoma Cells in Comparison to T-Cells Responsive to Subdominant Epitopes

T- Cell Depleted Peripheral Blood Stem Cell (TCD-PBSC) Transplants Secure Consistent Engraftment with Low Risk of Acute or Chronic Gvhd and Favorable Disease Free Survival (DFS) and Overall Survival (OS) for Pediatric Patients (<21 years) with AML in CR1 or CR2 or MDS Including tMDS/AML

Banked, GMP Grade Third Party T-Cell Lines Specific for CMVpp65 Epitopes Presented By Certain Prevalent HLA Alleles More Consistently Clear CMV Infections in a Genetically Heterogeneous Population of HSCT Recipients

Generation and Characterization Of a Third Party GMP Grade Bank Of CMV Specific T-Cells For Adoptive Immunotherapy Of CMV Infections In Recipients Of HSCT From Cord Blood Or Seronegative Donors

Two Chemotherapy-Based Conditioning Regimens Compared To TBI-Based Conditioning Secure Consistent Engraftment Of T-Cell Depleted Allogeneic HSCT, Similarly Low Incidences Of Gvhd and Favorable Rates Of Disease-Free Survival (DFS)

Adoptive Immunotherapy with Donor T Cells Sensitized with Overlapping Pentadecapeptides of the CMV-pp65 Protein for the Treatment of Persistent CMV Antigenemia Following Allogeneic Hematopoietic Stem Cell Transplants

Engineered Antigen- Presenting Cells Expressing Human HLA Class-II DR Alleles Support Efficient Enrichment and Expansion of Antigen Specific T h 1 CD4[+] T-Cells Which Are Functionally Augmented by IL-15Rα/IL-15 Complexes

A Panel of Artificial Antigen Presenting Cells (AAPC) Permits Immediate Sensitization and Rapid Generation of Virus-Specific T-Cells of Desired HLA Restriction for Adoptive Immunotherapy.

Re-Treatment with Rituximab in ITP: Comparison of Standard Dose with 2 Forms of Augmented Rituximab.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only